Compare Janus Living Inc. Class A-1 Common Stock (JAN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Janus Living Inc. Class A-1 Common Stock vs Summit Therapeutics Inc — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $28.51 (market cap $6.79B), while Summit Therapeutics Inc trades at $15 (market cap $12.07B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Janus Living Inc. Class A-1 Common Stock pays a 1.97% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and Summit Therapeutics Inc for 16 Days on average.
| JAN | SMMT | |
|---|---|---|
Market Cap | $6.79B | $12.07B |
Volume | 1,802,875 | 4,658,232 |
Sector | Real Estate | Health |
52-Week High | $31.76 | $26.38 |
52-Week Low | $22.88 | $12.43 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $6.88B | $11.40B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today despite recent positive catalysts including a $2 billion strategic investment from AstraZeneca announced September 28, 2026. The stock shows bullish technical signals with strong institutional support, though fundamentals reflect a pre-revenue biotech with significant losses (-$1.08B net income in 2025) and negative ROE of -192.5%. Recent clinical trial collaborations with major pharma partners highlight the company's promising ivonescimab cancer drug pipeline.
The outlook balances substantial upside potential from AstraZeneca's validation and clinical progress against high execution risks typical of developmental biotechs. With 65% analyst buy ratings and a $29.33 consensus target suggesting 89% upside, the stock offers high-risk/high-reward exposure to innovative cancer therapeutics, dependent on successful drug development and regulatory approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
